8-K current report · filed Sep 3, 2026

Apogee Therapeutics, Inc. (APGE) 8-K Current Report: September 3, 2026

Item 1.02Item 2.01Item 5.02Item 5.03Item 3.03Item 5.01Item 3.01APGE overview

Short answer

Apogee Therapeutics, Inc. (APGE) filed an 8-K current report with the SEC on September 3, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.01 (Changes in Control of Registrant), Item 3.01 (Notice of Delisting). Apogee terminated its 2023 Equity Incentive Plan effective at the transaction’s Effective Time.

  • This filing includes Item 3.01, an item that often signal trouble.

Why these 8-K items matter →

Apogee Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.02 · Termination of a Material Definitive Agreement

  • Apogee terminated its 2023 Equity Incentive Plan effective at the transaction’s Effective Time
  • Apogee also terminated its 2023 Employee Stock Purchase Plan
  • Termination ends these equity-based compensation and employee stock purchase programs; transaction context determines shareholder impact

Item 2.01 · Completion of Acquisition or Disposition of Assets

  • Item 2.01 contains no standalone acquisition or disposition details
  • Investors should review the referenced Introductory Note and Items 3.01, 3.03, 5.01, 5.02 and 5.03 for transaction implications

Item 3.01 · Notice of Delisting

  • Merger consummated, triggering APGE’s planned removal from Nasdaq
  • Trading halt maintained through September 3, 2026, with Nasdaq suspension beginning September 4, 2026
  • Form 25 filing will delist and deregister common stock under Exchange Act Section 12(b)
  • Planned Form 15 filing would terminate registration and suspend ongoing SEC reporting obligations

Item 3.03 · Material Modification to Rights of Security Holders

  • Merger converted each pre-closing share into the right to receive merger consideration, subject to tax withholding
  • Former Apogee shareholders lost voting and other stockholder rights at the merger effective time
  • Investor outcome depends on merger consideration terms referenced in the merger agreement

Item 5.01 · Changes in Control of Registrant

  • Merger completed, transferring control of Apogee to AbbVie
  • Apogee became AbbVie’s indirect wholly owned subsidiary
  • Transaction equity value approximately $10.9 billion
  • AbbVie funded the acquisition with cash on hand and debt
  • No known arrangements indicating another future change in control

Item 5.02 · Departure/Election of Directors or Officers

  • Merger replaced Apogee’s entire board with Merger Sub directors, signaling a complete governance transition
  • All Apogee executive officers left their positions at the merger’s effective time
  • Executive parachute-tax agreements cap aggregate company payments at $12.5 million
  • Potential Section 4999 excise-tax protection increases merger-related obligations to affected executives and directors

Item 5.03 · Amendments to Articles of Incorporation or Bylaws

  • Merger-triggered amendments replaced Apogee’s certificate of incorporation and bylaws in full
  • Revised governing documents became effective at the merger’s Effective Time
  • Shareholder rights, governance structure, and board authority may have changed, requiring review of Exhibits 3.1 and 3.2

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Apogee Therapeutics, Inc. 8-K filings

Get the next APGE 8-K as it lands

Follow APGE for push alerts, or ask the research agent what this filing means.